The contract adds a new revenue stream, but the contingent portion depends on SAB-142's clinical and regulatory success. Monitor SAB-142 trial updates and milestone announcements for revenue recognition triggers.
Price Chart
Executive Summary
Emergent BioSolutions announced a multi-year agreement with SAB Biotherapeutics to provide manufacturing services for SAB-142, a clinical-stage treatment for type 1 diabetes. The deal is valued at approximately $50 million, with $36 million contingent on regulatory milestones, providing moderate revenue upside for EBS.
Key Financial Metrics
Key Facts
- Emergent BioSolutions signs multi-year manufacturing agreement with SAB Biotherapeutics
- Agreement valued at ~$50 million, with $36 million contingent on regulatory approval and milestones
- Services include process development, scale-up, and manufacturing for SAB-142, a T1D treatment
- Manufacturing to take place at Emergent's Winnipeg facility
Financial Impact
Approximately $14 million in near-term revenue (guaranteed portion) with potential total of $50 million if all milestones met
Risk Factors
- Only $14M is guaranteed; $36M contingent on regulatory approval and milestones
- SAB-142 is in clinical development; risk of trial failure or regulatory delay
- Manufacturing contracts may have lower margins than proprietary products
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3283664 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 10, 2026 7w ago | Press Release | $4.45 $5.68 | ▼ −27.64% | ▼ −28.70% | $6.29 (−41.35%) |
Jun 29, 2026 13w ago | 8-K | $8.46 $7.26 | ▼ −14.18% | ▼ −13.90% | $6.29 (−25.65%) |
Jun 4, 2026 17w ago | Press Release | $8.44 $8.28 | ▼ −1.90% | ▼ −0.52% | $6.29 (−25.47%) |
Apr 30, 2026 22w ago | Press Release | $8.47 $8.49 | ▲ +0.24% | ▼ −5.05% | $6.29 (−25.74%) |
Apr 30, 2026 22w ago | Insider Cluster | $8.23 $9.18 | ▲ +11.54% | ▲ +6.58% | $6.29 (−23.57%) |
Apr 29, 2026 22w ago | Press Release | $7.99 $9.18 | ▲ +14.89% | ▲ +8.85% | $6.29 (−21.28%) |
Apr 29, 2026 22w ago | Press Release | $7.99 $9.18 | ▲ +14.89% | ▲ +8.85% | $6.29 (−21.28%) |
Apr 28, 2026 22w ago | DEFA14A | $8.23 $9.13 | ▲ +10.94% | ▲ +5.47% | $6.29 (−23.57%) |
Apr 28, 2026 22w ago | Press Release | $8.23 $9.13 | ▲ +10.94% | ▲ +5.47% | $6.29 (−23.57%) |
Apr 27, 2026 22w ago | DEFA14A | $8.23 $9.13 | ▲ +10.94% | ▲ +5.47% | $6.29 (−23.57%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access